Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC.
about
Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.Immunomodulatory oligonucleotides inhibit neutrophil migration by decreasing the surface expression of interleukin-8 and leukotriene B4 receptors.Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.
P2860
Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Treatment of multiple sclerosi ...... C chemokine receptors in PBMC.
@en
Treatment of multiple sclerosi ...... C chemokine receptors in PBMC.
@nl
type
label
Treatment of multiple sclerosi ...... C chemokine receptors in PBMC.
@en
Treatment of multiple sclerosi ...... C chemokine receptors in PBMC.
@nl
prefLabel
Treatment of multiple sclerosi ...... C chemokine receptors in PBMC.
@en
Treatment of multiple sclerosi ...... C chemokine receptors in PBMC.
@nl
P2093
P1476
Treatment of multiple sclerosi ...... C chemokine receptors in PBMC.
@en
P2093
Andrzej Glabinski
Andzelika Mazurek
Bartosz Bielecki
Paweł Wolinski
P2860
P2888
P304
P356
10.1007/S10875-007-9142-7
P577
2007-10-25T00:00:00Z